What this is
- How it works
- How it works isn't classified yet
- Tested for
- Bipolar Disorder I or II With a Major Depressive Episode
- Main trialPhase 2
- “The purpose of this study is to assess antidepressant efficacy differences between ALTO-100 and placebo during the Double-Blind period in patients with bipolar disorder I or II with current major depressive episode, when used adjunctively to a mood stabilizer and/or atypical antipsychotic, related to patient characteristics. Additionally, safety, tolerability, and efficacy will be assessed in a subsequent open label treatment period.”In the company’s words, NCT06656416 on ClinicalTrials.gov
Coming up1
- Sep 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Sep 2027 | ALTO-100 in Bipolar Disorder With Depression (BD-D) | |
| Phase 2Completed | 1 Dec 2022 | ALTO-100 in MDD and/or PTSD | |
| Phase 2Completed | 13 Jan 2023 | Pilot Decentralized Trial | |
| Phase 2Completed | 5 Sep 2024 | Phase 2b Study of ALTO-100 in MDD |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026